SOURCE: Kalorama Information

Kalorama Information

June 11, 2009 16:40 ET

New Report Forecasts More Than Doubling of Vaccine Sales by 2013

NEW YORK, NY--(Marketwire - June 11, 2009) - 2008 was another stellar year for the world vaccine market. Sales grew 21.5% since 2007 to reach $19.2 billion. Few areas of pharmaceuticals have seen the fast-moving developments in the marketplace that the vaccine market has. A new report from leading life science market research publisher Kalorama Information, "Vaccines 2009: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry," forecasts the market to more than double by 2013 due to a strong pipeline of new products and rising usage of current products around the world.

"New products and better-than-expected profits, as well as merger activity, have transformed the vaccine marketplace," says Bruce Carlson, publisher of Kalorama Information. "Continued sales of influenza and cervical cancer vaccines have provided a foundation for growth in the adult market. Meanwhile, the pediatric market was fueled by several major products including Wyeth's pneumococcal vaccines Prevnar and Merck's new rotavirus vaccine TotaTeq."

Though vaccination programs typically focus on children, adults in industrialized countries are more likely than children to die as a result of vaccine-preventable diseases. For example, vaccines can prevent about 50% of deaths from pneumococcal disease and 80% of deaths from influenza-related complications in the elderly. Immunization rates for these diseases continue to be low in at-risk populations, but increased educational efforts aiming to promote the benefits of immunization should contribute to continued growth.

Growth is also being fueled by vaccines that have recently been introduced or are in the approval process that address meningitis, swine flu, malaria, and Japanese encephalitis, as well as a growing number of combination vaccines which are enjoying one of the highest growth rates of any vaccine segment. Both Sanofi Pasteur's Penacel, which protects against pertussis, diphtheria, tetanus, polio and Haemophilus influenzae type B, and GlaxoSmithKline's Kimrix, which protects against pertussis, diphtheria, tetanus and polio, were approved by the FDA in mid-2008.

Kalorama Information's new report, "Vaccines 2009: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry," covers all the latest trends and issues for both pediatric and adult vaccines. Market data is broken down by type of vaccine, and includes market size and forecasts, product reviews and pipelines, and competitive analyses of leading providers. For further information visit:

About Kalorama Information

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services.

Contact Information